Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant falciparum malaria

Clinical Infectious Diseases

Volumn 56, Issue 5, 2013, Pages

  Das, Debashish ^a,d   Tripura, Rupam ^a   Phyo, Aung Pyae ^b   Lwin, Khin Maung ^b   Tarning, Joel ^a,c   Lee, Sue J ^a,c   Hanpithakpong, Warunee ^a   Stepniewska, Kasia ^c,d   Menard, Didier ^f   Ringwald, Pascal ^g   Silamut, Kamolrat ^a   Imwong, Mallika ^a   Chotivanich, Kesinee ^a   Yi, Poravuth ^e   Day, Nicholas P J ^a,c   Lindegardh, Niklas ^a,c   Socheat, Duong ^e   Nguon, Chea ^e   White, Nicholas J ^a,c   Nosten, François ^a,b,c   Dondorp, Arjen M ^a,c   more..

^a MAHIDOL UNIVERSITY   (Thailand)

^b SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d WorldWide Antimalarial Resistance Network   (United Kingdom)

^e National Center for Parasitology Entomology and Malaria Control   (Cambodia)

^f INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

^g WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

artemisinins; drug resistance; neutropenia; Plasmodium falciparum; reticulocytopenia

Indexed keywords

ARTESUNATE; DIHYDROARTEMISININ; MEFLOQUINE; QUININE;

ADULT; ANTIMALARIAL DRUG RESISTANCE; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CAMBODIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GAMETOCYTE; HALF LIFE TIME; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; NONHUMAN; PARASITE CLEARANCE; PARASITEMIA; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THAILAND; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIBODIES, PROTOZOAN; ANTIMALARIALS; ARTEMISININS; CAMBODIA; CHILD; DRUG RESISTANCE; FEMALE; HALF-LIFE; HUMANS; IMMUNOGLOBULIN G; MALARIA, FALCIPARUM; MALE; PARASITE LOAD; PARASITEMIA; PLASMODIUM FALCIPARUM; THAILAND; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873656674     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis958     Document Type: Article

References (23)

1. World Health Organization. Global report on antimalarial drug efficacy and drug resistance: 2000-2010. Geneva, Switzerland: WHO 2010.
2. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455-67.
3. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008; 359:2619-20.
4. Phyo AP, Nkhoma S, Stepniewska K, et al. Emergence of artemisininresistant malaria on the western border of Thailand: a longitudinal study. Lancet 2012; 379:1960-66.
5. Olliaro P, Wells TN. The global portfolio of new antimalarial medicines under development. Clin Pharmacol Ther 2009; 85:584-95.
6. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997; 41:1413-22.
7. White NJ. Qinghaosu (artemisinin): the price of success. Science 2008; 320:330-4.
8. Saralamba S, Pan-Ngum W, Maude RJ, et al. Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A 2011; 108:397-402.
9. Flegg JA, Guerin PJ, White NJ, Stepniewska K. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J 2011; 10:339.
10. Carrara VI, Sirilak S, Thonglairuam J, et al. Deployment of early diagnosis and mefloquine-artesunate treatment of falciparum malaria in Thailand: the Tak Malaria Initiative. PLoS Med 2006; 3:e183.
11. World Health Organization, Communicable Diseases Cluster. Severe falciparum malaria. Trans R Soc Trop Med Hyg 2000; 94(suppl 1): S1-90.
12. Bethell D, Se Y, Lon C, et al. Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria. Clin Infect Dis 2010; 51: e105-14.
13. World Health Organization. Methods for surveillance of antimalarial drug efficacy. Geneva, Switzerland: WHO, 2009.
14. Snounou G, Beck HP. The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. Parasitol Today 1998; 14:462-7.
15. Lindegardh N, Dondorp AM, Singhasivanon P, White NJ, Day NP. Validation and application of a liquid chromatographic-mass spectrometric method for determination of artesunate in pharmaceutical samples. J Pharm Biomed Anal 2007; 45:149-53.
16. Angus BJ, Thaiaporn I, Chanthapadith K, Suputtamongkol Y, White NJ. Oral artesunate dose-response relationship in acute falciparum malaria. Antimicrob Agents Chemother 2002; 46: 778-82.
17. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13:176-81.
18. Cao XT, Bethell DB, Pham TP, et al. Comparison of artemisinin suppositories, intramuscular artesunate and intravenous quinine for the treatment of severe childhood malaria. Trans R Soc Trop Med Hyg 1997; 91:335-42.
19. Tran TH, Day NP, Nguyen HP, et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 1996; 335:76-83.
20. Xie LH, Johnson TO, Weina PJ, et al. Risk assessment and therapeutic indices of artesunate and artelinate in Plasmodium berghei-infected and uninfected rats. Int J Toxicol 2005; 24:251-64.
21. Price R, Nosten F, Simpson JA, et al. Risk factors for gametocyte carriage in uncomplicated falciparum malaria. Am J Trop Med Hyg 1999; 60:1019-23.
22. Price RN, Nosten F, Luxemburger C, et al. Effects of artemisinin derivatives on malaria transmissibility. Lancet 1996; 347:1654-8.
23. McGready R, Phyo AP, Rijken MJ, et al. Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects. Br J Clin Pharmacol 2012; 73:467-77.